Clinical trial NCT04742673: Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study
Official title: Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Critical Illness
Delirium
Cognitive Impairment
Lead sponsor: Vanderbilt University Medical Center
Sponsor class: OTHER
Collaborators: name: Massachusetts General Hospital
name: National Institute on Aging (NIA)
First posted: 2021-02-08
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This proof-of-concept study examines whether the acute brain dysfunction that occurs in critically ill patients is improved by administration of intravenous guanfacine.

Detailed description: Delirium during critical illness is, to date, the primary potentially modifiable risk factor for acquired dementia after critical illness (ADRD). There are, however, no Food and Drug Administration (FDA) approved medications to mitigate delirium. Benzodiazepines are ineffective at reducing the incidence or duration of delirium, and on the contrary, increase the risk. Furthermore, large randomized controlled studies have shown that antipsychotic agents have no effect (vs. placebo) on delirium duration, mechanical ventilation, hospital length of stay, or death. Therefore, current clinical practice guidelines no longer recommend routine use of benzodiazepines or antipsychotics for treatment of delirium. Despite these recommendations, benzodiazepine, antipsychotics, and other drugs are routinely prescribed to critically ill patients due to the urgent clinical need to control delirium symptoms. The alpha-2 agonist dexmedetomidine is the most successful agent for delirium identified to date. However, it is typically administered as a continuous infusion and requires ICU-level monitoring due to hypotension and bradycardia risks. The delirium sparing benefits of dexmedetomidine have been postulated to result from alpha-2 agonist mediated modulation of CNS inflammation, microcirculatory blood flow, and biomimetic sleep.

The alpha-2 agonist guanfacine, an FDA-approved medication for use in hypertension and attention deficit hyperactivity disorder, has a higher selectivity for the alpha-2A receptor in the central nervous system. Thus, delirium sparing benefits may be improved with guanfacine while reducing systemic effects. Further, instead of a continuous infusion, the pharmacokinetic and pharmacodynamic properties of guanfacine favor a twice a day bolus dosing schedule. This Maximizing trEatment of Neurological Dysfunction using INtravenous Guanfacine (MENDING) study will investigate the benefits of intravenous (IV) guanfacine. In this phase II proof-of-concept trial of IV guanfacine vs. placebo for the treatment of critical illness delirium, the following specific aims will be tested in critically ill patients with delirium:

Aim 1: To determine whether IV guanfacine will increase the number of days alive without delirium and coma (DCFDs) over 14 days relative to placebo.

Aim 2: To evaluate whether IV guanfacine twice a day will increase days alive and free of mechanical ventilation (VFDs) and days alive and free of the ICU (IFDs) over 28 days relative to placebo.

Aim 3: To assess whether IV guanfacine can reduce the development of ADRD after critical illness.

Identifying a safe and effective treatment for delirium would have exponential benefits to patients, families, healthcare, and society. This first study of IV guanfacine builds upon extensive research regarding the benefits of alpha-2 agonists for brain dysfunction.

Eligibility criteria: Inclusion Criteria:

1. adult patients (≥ 18 years old)
2. requiring admission to an ICU
3. for treatment of respiratory failure (e.g., mechanical ventilation, non-invasive positive pressure ventilation \[NIPPV\], Extracorporeal Membrane Oxygenation \[ECMO\], optiflow) and/or for treatment of shock (e.g., vasopressors, ECMO, intra-aortic balloon pump \[IABP\]).

Exclusion Criteria:

1. allergic to guanfacine, clonidine, or dexmedetomidine
2. on home antipsychotics who, therefore, require continuing antipsychotic administration in the hospital
3. present history of 2nd or 3rd degree heart block, or persistent bradycardia \< 50 beats/minute that requires intervention (e.g., atropine, glycopyrrolate). If patient has a pacemaker for bradyarrythmias, then patient does not meet this exclusion criterion and may be enrolled.
4. co-enrolled in another interventional trial examining similar outcomes or in a study that does not allow co-enrollment
5. expected death within 24 hours of enrollment or lack of commitment to aggressive treatment by family or the medical team (e.g., likely withdrawal of life support measures within 24 hours of screening)
6. acute or subacute neurologic deficit that is expected to make the patient incapable of living independently after hospital discharge due to cognitive deficits (e.g., stroke, intracranial hemorrhage, cranial trauma, intracranial malignancy, anoxic brain injury, cerebral edema).
7. dementia or other chronic neurologic disease or disorder that makes the patient incapable of living independently at baseline
8. active substance abuse, psychotic disorder, or homelessness without a secondary contact person (which would make long-term follow-up difficult)
9. blindness or deafness (which would prevent assessment of the study's outcomes)
10. pregnancy or breastfeeding
11. prisoner
12. inability to start informed consent process within 72 hours from the time that all inclusion criteria were met
13. Cardiac surgery within the current hospitalization.

Primary outcomes:
measure: Number of Days Alive Without Delirium or Coma
timeFrame: 14 days after randomization
Secondary outcomes:
measure: Days Alive and Free of Mechanical Ventilation
timeFrame: 28 days after randomization
measure: Days Alive and Free of the Intensive Care Unit
timeFrame: 28 days after randomization
measure: Cognitive Function
timeFrame: 180 days after randomization
measure: Days Alive and Free of the Hospital
timeFrame: 28 days after randomization
measure: Mortality
timeFrame: 90 days after randomization
Other outcomes:
measure: Physical Function
timeFrame: 180 days after after randomization
measure: Global Health
timeFrame: 180 days after after randomization
measure: Pain Interference
timeFrame: 180 days after randomization
measure: Applied Cognition
timeFrame: 180 days after randomization
measure: Sleep
timeFrame: up to 180 days after hospital discharge
measure: Co-administration of Analgesics
timeFrame: 14 days after randomization
measure: Hypotension
timeFrame: 14 days after randomization, while on study drug
measure: Bradycardia
timeFrame: 14 days after randomization, while on study drug
measure: Mental Status
timeFrame: 14 days after randomization, while on study drug
Locations:
city: Nashville
country: United States
facility: Vanderbilt University Medical Center
state: Tennessee
Study officials:
affiliation: Vanderbilt University Medical Center
name: Christopher Hughes, MD
role: PRINCIPAL_INVESTIGATOR
References: